Tamoxifen retards glycosphingolipid metabolism in human cancer cells

FEBS Letters

Volumn 394, Issue 2, 1996, Pages 129-131

  Cabot, Myles C ^a   Giuliano, Armando E ^a   Volner, Alon ^a   Han, Tie Yan ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Cancer; Glucosylceramide; Glycosphingolipids; Multidrug resistance; Tamoxifen

Indexed keywords

GANGLIOSIDE; GLUCOSYLCERAMIDE; LACTOSYLCERAMIDE; TAMOXIFEN;

ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL STRAIN KB; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; METABOLISM; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0030607216     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-5793(96)00942-8     Document Type: Article

References (32)

1. [1] Ecker, R.L. and Katzenellenbogen, B.S. (1983) J. Biol. Chem. 257, 8840-8846.
2. [2] Coezy, E., Borgna, J.L. and Rochefort, H. (1982) Cancer Res. 42, 317-323.
3. [3] Kellen, J.A. (1996) Tamoxifen - Beyond the Antiestrogen. Birkhäuser, Boston, MA.
4. [4] Wiseman, H. and Halliwell, B. (1994) Free Radical Biol. Med. 17, 485-488.
5. [5] Knabbe, C., Lippman, M.E., Wakefield, L.M., Flanders, K.C., Kasid, A., Derynck, R. and Dickson, R.B. (1987) Cell 48, 417-428.
6. [6] O'Brian, C.A., Liskamp, R.M., Solomon, D.H. and Weinstein, I.B. (1985) Cancer Res. 45, 2462-2465.
7. [7] Lavie, Y., Jones, R.C., Cao, H.-t., Jarman, M., Hardcastle, I.R., Giuliano, A.E. and Cabot, M.C. (1996) Proc. Am. Assoc. Cancer Res. 37, 423.
8. [8] Gundimeda, U., Chen, Z.-H. and Gopala-Krishna (1996) J. Biol. Chem. 271, 13504-13514.
9. [9] Cabot, M.C., Zhang, Z.-C. and Giuliano, A.E. (1995) Breast Cancer Res. Treat. 36, 299-306.
10. [10] Rowlands, M.G., Parr, I.B., McCague, R., Jarman, M. and Goddard, P.M. (1990) Biochem. Pharmacol. 40, 283-289.
11. [11] Couldwell, W.T., Weiss, M.H., DeGiorgio, C.M., Weiner, L.P., Hinton, D.R., Ehresmann, G.R., Conti, P.S. and Apuzzo, M.L. (1993) Neurosurgery 32, 485-489.
12. [12] DelPrete, S.A., Maurer, L.H., O'Donnel, J., Forcier, J.R. and LeMarbre, P. (1984) Cancer Treat. Rep. 68, 1403-1405.
13. [13] Ramu, A., Glaubiger, D. and Fuks, Z. (1984) Cancer Res. 44, 4392-4395.
14. [14] Raderer, M. and Scheithauer, W. (1993) Cancer 72, 3553-3563.
15. [15] Millward, M.J., Cantwell, B.M.J., Lien, E.A., Carmichael, J. and Harris, A.L. (1992) Eur. J. Cancer 28A, 805-810.
16. [16] Trump, D.L., Smith, D.C., Ellis, P.G., Roger, M.P., Schold, S.C., Winer, E.P., Panella, T.J., Jordan, V.C. and Fine, R.L. (1992) J. Natl. Cancer Inst. 84, 1811-1816.
17. [17] Lavie, Y., Cao, H.-t., Bursten, S.L., Giuliano, A.E. and Cabot, M.C. (1996) J. Biol. Chem. 271, 19530-19536.
18. [18] Welsh, C.J., Yeh, G.C. and Phang, J.M. (1994) Biochem. Biophys. Res. Commun. 202, 211-217.
19. [19] Kiss, Z. (1994) FEBS Lett. 355, 173-177.
20. [20] Cabot, M.C. and Giuliano, A.E. (1996) in: Tamoxifen - Beyond the Antiestrogen (Kellen, J.A., Ed.), pp. 43-58, Birkhäuser, Boston, MA.
21. [21] Kirk, J., Syed, S.K., Harris, A.L., Jarman, M., Roufogalis, B.D., Stratford, I.J. and Carmichael, J. (1994) Biochem. Pharmacol. 48, 277-285.
22. [22] Callaghan, R. and Higgins, C.F. (1995) Br. J. Cancer 71, 294-299.
23. [23] McClay, E.F., Albright, K.D., Jones, J.A., Christen, R.D. and Howell, S.B. (1993) Cancer Res. 53, 1571-1576.
24. [24] Doige, C.A., Yu, X. and Sharom, F.J. (1999) Biochim. Biophys. Acta 1146, 65-72.
25. [25] Wadkins, R.M. and Houghton, P.J. (1993) Biochim. Biophys. Acta 1153, 225-236.
26. [26] Tsuchida, T., Saxton, R.E. and Irie, R.F. (1987) J. Natl. Cancer Inst. 78, 55-60.
27. [27] Bligh, E.G. and Dyer, W.J. (1959) Can. J. Biochem. Physiol. 137, 911-917.
28. [28] Shukla, G.S. and Radin, N.S. (1990) Arch. Biochem. Biophys. 283, 372-378.
29. [29] Hannun, Y.A. and Bell, R.M. (1989) Science 243, 500-507.
30. [30] Hakomori, S. (1981) Annu. Rev. Biochem. 50, 733-764.
31. [31] Morton, D.L., Ravindranath, M.H. and Irie, R.F. (1994) Prog. Brain Res. 101, 251-275.
32. [32] Fukuda, M.N., Dell, A., Tiller, P.R., Varki, A., Klock, J.C. and Fukuda, M. (1986) J. Biol. Chem. 261, 2376-2383.